Lift Procedures Led Growth as Demand for Restoration Drove Plastic Surgery in 2025, New ASPS Report Reveals

ASPS reported 2025 cosmetic procedure volume rose 7% YoY, led by liposuction, breast augmentation, and tummy tucks. Minimally invasive procedures were dominated by neuromodulators and hyaluronic fillers (80% share), while reconstructive procedures grew 6% YoY; facial fat grafting jumped 39% with lift categories broadly higher (e.g., brow lifts +29%, forearm lifts +22%, facelifts +13%). The report also notes rising consultations tied to GLP-1 weight loss and increased preference for breast implant size, alongside a 24% procedure-volume rise among patients 66+ (while 18–25 fell 9%).

Analysis

This reads more like confirmation of a durable elective-spend cycle than a fresh catalyst. The actionable takeaway is that demand is bifurcating toward higher-ticket restoration, which should favor surgeons, anesthesia centers, and suppliers of implant/filler ecosystems over pure consumer-beauty brands that rely on younger, trend-driven traffic. Public-market implication is modest in the next few days, but the 1-3 month read-through matters for Q3/Q4 commentary: if management teams in aesthetics, devices, or ambulatory surgery cite broader case mix, the multiple can rerate even without headline unit acceleration.

Second-order, the age skew is important: older patients and post-weight-loss body contouring are less promotional and more medically justified, so the volume base should be stickier than the typical fashion cycle. That supports names with recurring consumables or procedure-linked revenue, while consumer-discretionary exposures tied to entry-level beauty spending look more vulnerable if macro softens. The GLP-1 angle is also underappreciated as a mix shift: it may create demand for correctional procedures, but it can also cannibalize some legacy weight-loss-related cosmetic spending and compress the tail of low-end medspa demand.

Contrarian view: the market may be overreading this as a clean beneficiary setup for every aesthetics supplier. The association data is not company revenue, and the strongest growth appears concentrated in procedures that are often capacity- and surgeon-limited, which means supply constraints could capture economics more than volume-sensitive public equities. The thesis breaks if consumer credit tightens, if GLP-1 adoption slows, or if elective demand normalizes in the next two quarters.

Key Decisions for Investors

• No immediate high-conviction trade; treat this as a watch item and wait for public-company evidence in Q3 earnings on procedure mix, not just topline sentiment.
• Prefer a small basket long in aesthetics enablers on pullbacks, led by INMD and EOLS, but only if channel checks confirm that restoration/body-contouring demand is translating into orders; upside is a gradual multiple expansion, not a sharp earnings beat.
• Avoid chasing medspa/entry-level beauty exposure until we see whether older, higher-ticket demand offsets softness in the 18-25 cohort; if public comps show traffic deceleration, that would favor shorts in the more consumer-sensitive names.
• Set an alert for management commentary on GLP-1-related consults and post-weight-loss procedures over the next 1-3 months; if the theme is confirmed in bookings, scale into a long basket, but if it is still anecdotal, fade the move.